Crispr Therapeutics AG vs ING Groep NV — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.17B), while ING Groep NV trades at $35.49 (market cap $101.24B). The key difference: ING Groep NV is far larger — about 19.6× Crispr Therapeutics AG's market cap, and ING Groep NV pays a 3.74% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ING | |
|---|---|---|
Market Cap | $5.17B | $101.24B |
Sector | Health | Financials |
52-Week High | $76.78 | $35.92 |
52-Week Low | $44.34 | $23.66 |
Enterprise Value | $3.59B | — |
Dividend Yield | — | 3.74% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →